Effect of metformin in COVID-19 symptom improvement and death

Effect of metformin in COVID-19 mortality rate and symptom improvement

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160310026998N11

Enrollment

200

Registered

2020-03-27

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

corona virus or COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: in addition to standard regimen of covid-19 patients will be administered Metformin 500 mg BID orally for 2 weeks. Intervention 2: Control group: standard regimen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with Covid-19 symptoms in patients with the history of close contact with suspected people in the last 14 days fever pulmonary involvement normal or reduced cbc reduced lymphocyte, positive PCR

Exclusion criteria

Exclusion criteria: patients with type I diabetes Ketoacidosis decompensated heart failure severe kidney failure (GFR<30 ml/min) metabolic acidosis severe respiratory failure immediate need for intubation

Design outcomes

Primary

Measure	Time frame
Decreased hospitalization period. Timepoint: at baseline and discharge time. Method of measurement: counting the day.;Mortality rate. Timepoint: at baseline and discharge time. Method of measurement: observation.;Decreased need for intubation. Timepoint: at baseline and discharge time. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaba Ghaffary

Tabriz University of Medical Sciences

ghaffarys@tbzmed.ac.ir+41 33365010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026